Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Breast Neoplasms 3Uterine Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcopenia 1Salivary Gland Neoplasms 1Recurrence 1Primary Breast Cancer 1Peritoneal Neoplasms 1Pathologic Complete Response 1Neutropenia 1Neoplasms, Unknown Primary 1Neoplasms 1NSCLC 1Melanoma 1Malnutrition 1Head and Neck Neoplasms 1

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Tamoxifen 1Paclitaxel 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Primary Breast Cancer × CP protocol × Clear all
NCT01314833 2020-05-19

Minus Anthracycline or Short-Term Versus Epirubicin and Cyclophosphamide Followed by Paclitaxel Regimen for Adjuvant Breast Cancer Therapy

Fudan University

Phase 3 Completed
1,570 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡